Education
About Us
Working with TipRanks
Follow Us
Seres Therapeutics Inc. (MCRB)
NASDAQ:MCRB
MCRB Stock Chart & Stats
$15.63
>-$0.01(-0.25%)
At close: 4:00 PM EST
$15.63
>-$0.01(-0.25%)
Day’s Range― - ―
52-Week Range$6.53 - $29.98
Previous CloseN/A
Volume457.00K
Average Volume (3M)48.80K
Market Cap
$136.96M
Enterprise Value$175.85M
Total Cash (Recent Filing)$47.64M
Total Debt (Recent Filing)$85.25M
Price to Earnings (P/E)25.2
Beta1.57
Next Earnings
Mar 10, 2026EPS Estimate
-2.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.94
Shares Outstanding9,046,519
10 Day Avg. Volume41,892
30 Day Avg. Volume48,805
Financial Highlights & Ratios
PEG Ratio154.14
Price to Book (P/B)9.37
Price to Sales (P/S)0.00
P/FCF Ratio-0.87
Enterprise Value/Market Cap1.28
Enterprise Value/Revenue500.99
Enterprise Value/Gross Profit-10.00
Enterprise Value/Ebitda18.18
Forecast
1Y Price Target
$22.00Price Target Upside40.75% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Analyst EndorsementAnalyst's BUY rating based on the potential of SER-155 in allogeneic transplant settings signals market confidence and may help underpin investor interest as development milestones are achieved.
Clinical CollaborationInvestigator-led study at Memorial Sloan Kettering investigating SER-155 in immune checkpoint related enterocolitis could generate supportive clinical evidence that broadens the therapy's potential indications.
Regulatory ProgressConstructive FDA feedback on the Phase II study design for SER-155 in allogeneic hematopoietic stem cell transplantation and work to finalize the protocol support continued advancement of the clinical program.
Bears Say
Financing RiskNeed for additional capital to support the Phase II study exposes the company to dilution or financing risk that could weigh on the stock if funding is not secured on favorable terms.
Partnership DependencyReliance on securing a partnership to fund the Phase II trial creates execution risk, since delays or unfavorable partnership terms could postpone study progress and limit upside.
Seres Therapeutics News
MCRB FAQ
What was Seres Therapeutics Inc.’s price range in the past 12 months?
Seres Therapeutics Inc. lowest stock price was $6.53 and its highest was $29.98 in the past 12 months.
What is Seres Therapeutics Inc.’s market cap?
Seres Therapeutics Inc.’s market cap is $136.96M.
When is Seres Therapeutics Inc.’s upcoming earnings report date?
Seres Therapeutics Inc.’s upcoming earnings report date is Mar 10, 2026 which is in 39 days.
How were Seres Therapeutics Inc.’s earnings last quarter?
Seres Therapeutics Inc. released its earnings results on Nov 05, 2025. The company reported $0.94 earnings per share for the quarter, beating the consensus estimate of $0.457 by $0.483.
Is Seres Therapeutics Inc. overvalued?
According to Wall Street analysts Seres Therapeutics Inc.’s price is currently Undervalued.
Does Seres Therapeutics Inc. pay dividends?
Seres Therapeutics Inc. does not currently pay dividends.
What is Seres Therapeutics Inc.’s EPS estimate?
Seres Therapeutics Inc.’s EPS estimate is -2.11.
How many shares outstanding does Seres Therapeutics Inc. have?
Seres Therapeutics Inc. has 9,046,519 shares outstanding.
What happened to Seres Therapeutics Inc.’s price movement after its last earnings report?
Seres Therapeutics Inc. reported an EPS of $0.94 in its last earnings report, beating expectations of $0.457. Following the earnings report the stock price went down -7.636%.
Which hedge fund is a major shareholder of Seres Therapeutics Inc.?
Currently, no hedge funds are holding shares in MCRB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Seres Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$22.00 (40.75% Upside)
$22.00 (40.75% Upside)
Blogger Sentiment
Bullish
MCRB Sentiment 100%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 6.5%
Last 30 Days ▼ 6.5%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-6.96%
12-Months-Change
Fundamentals
Return on Equity
15.95%
Trailing 12-Months
Asset Growth
-19.73%
Trailing 12-Months
Company Description
Seres Therapeutics Inc.
Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the treatment of clostridium difficile infection (CDI). It is also developing SER-155, a cultivated bacteria microbiome drug, which is Phase Ib clinical trial to reduce incidences of gastrointestinal infections, bloodstream infections, and graft versus host diseases in immunocompromised patients receiving allogeneic hematopoietic stem cell transplantation and solid organ transplants. In addition, the company engages in the development of SER-287 and SER-301 that are in Phase Ib to treat ulcerative colitis; SER-401 for patients with metastatic melanoma; and SER-262 to treat Clostridioides difficile infection. It has license and collaboration agreements with Nestec Ltd. and Memorial Sloan Kettering Cancer Center. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
MCRB Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted significant clinical progress and financial recovery, supported by external funding and strategic cost reductions. However, the dependency on securing further capital for future studies poses a notable challenge.View all MCRB earnings summariesMCRB Stock 12 Month Forecast
Average Price Target
$22.00
▲(40.75% Upside)
Technical Analysis
Anixa Biosciences
―
Surrozen
―
Cognition Therapeutics
―
Immix Biopharma
―
CAMP4 Therapeutics Corporation
―
Ownership Overview
2.44% Insiders
4.54% Mutual Funds
15.85% Other Institutional Investors
72.91% Public Companies and
Individual Investors